Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Barney Graham · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2019 · $1,903,044 — While the outbreak of ZIKV in the Americas is likely to subside in the next 1-2 years, there is going to be an ongoing risk of congenital Zika syndrome in babies born to mothers exposed to ZIKV during pregnancy. There is no licensed vaccine or treatment to combat ZIKV infection. Because of the urgen…
ALASDAIR C. STEVEN · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · 2019 · $971,515 — In FY19, we continued with two projects already outlined in the Annual Report for FY18. In one, a continuing collaboration with E. Freed (NCI), we analyzed the role of a conserved Pro-Pro-Ile-Pro (PPIP) motif (CA residues 122-125 in the loop connecting helices 6 and 7 of CA) in HIV-1 assembly. Prior…
CATHERINE MARY O'CONNELL · UNIV OF NORTH CAROLINA CHAPEL HILL · 2019 · $202,527 — In a subset of Chlamydia trachomatis-infected women, the infection escapes immune control and ascends to the upper reproductive tract. There is a fundamental gap in understanding how pathways activated by chlamydial infection lead to immune pathology and reproductive morbidity in women. Its continue…
GARRY P NOLAN · STANFORD UNIVERSITY · 2019 · $313,000 — PROJECT SUMMARY New technologies such as mass cytometry have greatly expanded our ability to deepen our understanding of the complexity of lymphocytes and related populations. The Stanford CCHI group has been particularly attuned to the potential in following the lead of the Nolan lab in exploiting …
LOUISE C. SHOWE · WISTAR INSTITUTE · 2019 · $221,010 — PROJECT SUMMARY – GENOMICS SHARED RESOURCE The Genomics Shared Resource (GSR) provides state-of-the-art infrastructure and support for integrated functional genomics studies of Cancer Center (CC) investigators. The highly trained staff and their efforts to maintain costs without diminishing service,…
Jiang Zhu · INTERNATIONAL AIDS VACCINE INITIATIVE · 2019 · $280,575 — Project Summary Broadly neutralizing antibodies (bnAbs) recognize conserved epitopes on the envelope glycoprotein (Env) of the human immunodeficiency virus type-1 (HIV-1). Atomic structures of the BG505 SOSIP.664 gp140 trimer have provided a rational framework for Env-based HIV-1 vaccine design. …
Frederick Porter · DUKE UNIVERSITY · 2019 · $1,059,206 — Project 2: Current Good Manufacture Practices (CGMP) Production of Nucleoside-Modified mRNAs Encoding HIV-1 Envelopes This IPCAVD grant seeks to develop and evaluate mRNA as an HIV-1 vaccine platform. Project 2 will oversee the manufacture of two nucleoside-modified mRNAs by current good manufacturi…
Matthew Adrian Coleman · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · 2019 · $404,899 — ABSTRACT Throughout the world Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial pathogen. In countries with poor sanitary conditions ocular infections with Ct can result in trachoma, the most frequent cause of preventable blindness worldwide. Based on protection and serolo…
MARK J SHLOMCHIK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2019 · $577,514 — Immune memory is critical for pathogen resistance as well as for vaccine efficacy; it is a defining feature of adaptive immunity. To deepen our fundamental understanding of how immune memory works we have fo- cused on elucidating the inherent differences between memory B cells (MBC) and naïve B cell…
Julie Magarian Blander · WEILL MEDICAL COLL OF CORNELL UNIV · 2019 · $419,267 — PROPOSAL SUMMARY Live attenuated vaccines have proven to be the most efficient human vaccines for many serious infectious diseases. When compared to their dead counterparts, live vaccines induce superior immune protection and lasting memory. But despite the efficacy of live vaccines, concerns over t…
Darrell J Irvine · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2019 · $509,932 — PI: Irvine, Darrell J. Project Summary/Abstract: Strategies to promote the magnitude and quality of T cell and antibody responses following immunization have broad relevance for the development of new prophylactic and therapeutic vaccines for the treatment of cancer and infectious diseases. Recent s…
John T Chang · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2019 · $569,957 — Project Summary Mortality from infectious diseases remains a leading cause of death worldwide, making the development of new vaccines an important priority of biomedical research. Immunologic memory is a cardinal feature of adaptive immunity and an important goal of vaccination strategies. Traditio…
Mark T Heise · UNIV OF NORTH CAROLINA CHAPEL HILL · 2019 · $192,793 — Abstract Zika virus (ZIKV) is a mosquito borne flavivirus that recently emerged in the Americas. ZIKV infection is associated with severe disease outcomes, including Guillain-Barré syndrome and microcephaly, a devastating congenital disorder where fetal brain development is impaired. Despite ZIKV’s …
Barton F. Haynes · DUKE UNIVERSITY · 2019 · $3,513,157 — A key goal of HIV-1 vaccine development is to induce long-lasting broadly neutralizing antibodies (bnAbs) that can inhibit HIV-1 infection. Messenger (m) RNA has emerged as a promising new vaccine modality that can elicit potent immune responses, while avoiding the safety risks and anti-vector immun…
ANEEL K. AGGARWAL · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2019 · $254,250 — The Flavivirus genus includes mosquito-borne human pathogens, such as dengue virus, yellow fever virus, and the Zika virus (ZIKV), among others. ZIKV's recent spread in Americas and its link to microcephaly in newborn infants and the Guillan-Barré syndrome in adults has invigorated efforts to develo…
Ian J Mohr · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2019 · $399,509 — DESCRIPTION (provided by applicant): Regulation of gene expression at the level of translation allows both cells and organisms to respond swiftly to physiological stress and changing environments. Indeed, differential translation of capped, polyadenylated mRNAs by eukaryotic ribosomes plays a c…
JOHN H. SAMPSON · DUKE UNIVERSITY · 2019 · $413,970 — ABSTRACT We have previously reported in Nature that patients with newly-diagnosed glioblastoma (GBM) randomized to receiving vaccines against Cytomegalovirus (CMV) using a potent vaccine site preconditioning regimen had a statistically significant increase in progression-free survival (PFS) and over…
Florian Hladik · UNIVERSITY OF WASHINGTON · 2019 · $502,606 — DESCRIPTION (provided by applicant): We have recently shown that human semen contains trillions of extracellular vesicles (SEV) carrying small extracellular RNA (exRNA) molecules that may regulate the immune system (Nucleic Acids Research, 42:7290-7304, 2014). In unpublished studies, we have fo…
DREW WEISSMAN · UNIVERSITY OF PENNSYLVANIA · 2019 · $836,210 — DESCRIPTION (provided by applicant): A single HIV vaccine in human clinical trials demonstrated low level and short-term effectiveness, RV144. This vaccine used Pox virus prime - protein boost methodology, which because of the live virus prime, presents difficulties for large scale production a…
Mark T Heise · UNIV OF NORTH CAROLINA CHAPEL HILL · 2019 · $192,793 — Abstract Chikungunya virus (CHIKV) is a mosquito borne alphavirus that causes massive outbreaks of severe debilitating arthritis in humans (1). Despite CHIKV’s status as a significant emerging disease threat, there are currently no approved vaccines or therapies for CHIKV. Therefore, the development…